--- title: 'Senior Manager, Quality Control Operations, Global Analytics at Vaxcyte' canonical: 'https://feeny.ai/job/senior-manager-quality-control-operations-global-analytics-vaxcyte-visp-valais-zk3f2zsjs7r8' type: 'job' last_seen: '2026-10-19' --- # Senior Manager, Quality Control Operations, Global Analytics at Vaxcyte - **Company:** Vaxcyte - **Location:** Visp Valais, Switzerland - **Posted:** 2026-10-05 - **Last confirmed live:** 2026-10-19 - **Apply:** https://boards.greenhouse.io/vaxcyte/jobs/5440646008?gh_jid=5440646008 ## Job description Join our Mission to Protect Humankind! Vaxcyte is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, which have serious and costly health consequences when left unchecked. Working to eradicate or treat bacterial infections such as invasive pneumococcal disease, Group A Strep, and Shigella is just the beginning. Our path to success is clear and well-defined, and Vaxcyte is set up to go the distance. WHAT we do is every bit as important as HOW we do it! Our work together is guided by four enduring core values: *RETHINK CONVENTION: We bring creative and intellectual diversity to every facet of the work we do in order to innovate and re-innovate the way vaccines are delivered. *AIM HIGH: We embody our collectively audacious goal to courageously make the most complex biologics ever attempted to protect humankind. *LEAD WITH HEART: Everyone leads at Vaxcyte with a kindness-first, inclusive approach to collaboration and vigorous debate that advances our business objectives. *MODEL EXCELLENCE:  The magnitude of our challenge requires our shared commitment to demonstrating integrity, accountability, equality and clarity across communications and decision making. Summary: As Vaxcyte’s products progress towards late stage and commercialization, we are looking for people with experience in Quality Control for late stage or commercial products to strengthen our global Quality Control team. Within that Quality Control Organization, we are seeking a Senior Manager Quality Control acting as single point of contact for our CDMO in Europe. The Senior Manager QC will represent the executive function of QC ensuring analytical strategies are implemented at our CDMO and/or external testing lab to ensure the quality, accuracy, and compliance of testing and analytical services. Working closely with the analytical technical lead and other functions within Analytics, Process Development, Quality Assurance, Operations, and Regulatory functions, this role is accountable that testing and release is performed at our CDMO in a timely and compliant manner to ensure secure and uninterrupted supply of Vaxcyte’s innovative therapies. Essential Functions: - Implement the analytical control strategy for our programs at our CDMO/contract labs and ensure they are aligned with the CDMO's goals and objectives as well as comply with relevant regulations and industry standards. - Implement, and maintain robust quality control systems that encompass sampling, testing, documentation, and release procedures. - Ensure on-time performance for QC testing at our CDMO’s or contract laboratories related to raw materials, intermediates, and drug substance - Ensure that contracted QC laboratories are equipped with appropriate instrumentation and equipment, maintained according to regulatory requirements, and calibrated regularly to ensure accuracy and reliability of test results. - In partnership with analytical technical lead and analytical science and technology as well as the contract laboratories, oversee method validation and transfer activities between contract laboratories. - Assure that appropriate systems for data management, including secure storage, retrieval, and retention of QC data and documentation are in place. Ensure that all testing activities are well-documented and comply with Good Documentation Practices (GDP). - Review and approval of analytical data, test reports, and certificates of analysis (CoAs) generated by contract laboratories to verify accuracy, completeness, and compliance with specifications for both release and stability testing. - Support investigations and deviations, out-of-specification (OOS), out-of-trend (OOT), out-of-expectation (OOE) results, laboratory incidents, and customer complaints related to contract laboratory testing, collaborating with contract laboratories and internal stakeholders to implement corrective and preventive actions (CAPAs). - Provide technical support for product related inspections by Health Authorities. - Writing, review and approval of documents related to Quality Control to ensure compliance with applicable regulatory and industry standards. Requirements: - Bachelor of Science with minimum 8 years of relevant experience in biotechnology/pharmaceutical industry. - Experience in Pneumococcal vaccines is a plus. - Excellent experience in managing CDMOs and/or contract laboratories. - Comprehensive knowledge in cGMP and experience in multi-national regulations. - Excellent communication, negotiation, and relationship-building skills, with the ability to collaborate effectively with internal and external stakeholders. - Strong analytical and problem-solving abilities, with a focus on data-driven decision-making and continuous improvement. - Strong teamwork and interpersonal skills. - Relentless focus and passion around process improvements (efficiency and automation). Reports to: Director, QC Business Operations Location: Visp, Switzerland Work Arrangement (may be adjusted based on business needs, job responsibilities, or changes to company policy): Hybrid (minimum of 3 days per week onsite) Compensation: The compensation package will be competitive and includes an equity component. Relocation: This role is not eligible for relocation assistance. ## Equal Opportunity We are an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability or veteran status. Recruitment Fraud Notice Please be aware of fraud or scams from individuals, organizations and/or internet sites claiming to represent Vaxcyte in recruitment activities. Vaxcyte has an established recruitment process for all positions prior to issuing an offer for employment and we will never extend unsolicited employment offers or ask candidates to provide financial or sensitive personal information as part of the application process. All legitimate communication from Vaxcyte will come from an official @vaxcyte.com email address. Qualified and interested candidates should apply to current openings at [vaxcyte.com/careers](https://vaxcyte.com/careers/). ## About Vaxcyte ## Company Overview - **One-liner**: Vaxcyte is a clinical-stage biotechnology company re-engineering how vaccines are made to eliminate bacterial infections, using a cell-free protein synthesis platform to develop high-fidelity, broad-spectrum vaccines. - **Entity Type**: Public (Ticker: PCVX) - **Headquarters**: San Carlos, California, United States - **Founded**: 2013 (as SutroVax; rebranded to Vaxcyte in 2020) - **Founders**: Not publicly available (the company emerged from Sutro Biopharma’s spin-out) ## Core Business - **Primary industry**: Biotechnology / Vaccines (Infectious Disease) - **Target customers**: Global healthcare systems, public health organizations, and ultimately patients (B2B/Institutional); the company develops vaccines for both pediatric and adult populations. - **Mission or purpose**: To protect humankind from the consequences of bacterial infections, eliminating diseases like invasive pneumococcal disease, Group A Strep, and Shigella. ## Products & Services - **VAX-31 (31-valent PCV)**: A broad-spectrum pneumococcal conjugate vaccine candidate in Phase 3 for adults and Phase 2 for infants. Designed to cover over 95% of circulating IPD serotypes in U.S. adults 50+ and ~94% in infants. FDA Breakthrough Therapy designation granted. - **VAX-24 (24-valent PCV)**: A pneumococcal conjugate vaccine candidate in Phase 2 for infants, designed to cover more serotypes than any infant PCV on the market today. - **VAX-A1 (Group A Strep)**: A preclinical conjugate vaccine candidate for Group A Strep, a disease with no currently approved vaccine. Phase 1 first-in-human study (adults) underway in Australia. - **VAX-GI (Shigella)**: A novel preclinical vaccine candidate targeting Shigella, a leading cause of diarrheal disease. - **Platform Technology**: A proprietary cell-free protein synthesis platform that enables site-specific, carrier-sparing conjugation to produce precisely targeted vaccines with enhanced immunogenicity. ## Market Standing - **Valuation/Market Cap**: ~$16.7 billion (as of early July 2026) - **Key Metric**: Total funding raised (private) is not applicable; as a public company, key metrics include cash position (~$2.0 billion as of Q1 2026) and R&D investment. The company is pre-revenue. - **Notable Investors/Partners**: Major institutional investors include Baker Bros. Advisors, Fidelity, and funds managed by BlackRock. Key partnership: exclusive license agreement with Sutro Biopharma for its cell-free protein synthesis platform. - **Growth Signals**: - Up to $1 billion commitment to expanding U.S. manufacturing with a new facility in North Carolina. - VAX-31 Phase 3 program (OPUS-1, OPUS-2, OPUS-3) topline data expected Q4 2026 – H1 2027. - Headcount growth: actively hiring across 100+ roles (Analytical, Commercial, Clinical, Conjugation, Quality, Regulatory). - Recognized as a Great Place to Work and Best Workplace in BioPharma (multiple years). ## Competitive Advantages - **Broadest-spectrum PCV candidates**: VAX-31 is the broadest-spectrum pneumococcal conjugate vaccine in the clinic, targeting up to 31 serotypes. - **Differentiated platform**: Cell-free protein synthesis allows for the creation of complex, high-fidelity vaccines that can overcome bacterial defense mechanisms (e.g., capsule-switching) that limit conventional cell-based vaccines. - **Carrier-sparing technology**: Site-specific conjugation enables a higher valency (more serotypes) without compromising immunogenicity or tolerability. - **Manufacturing scale**: Significant investment in U.S.-based production capacity provides a long-term supply chain advantage and aligns with "Investing in America" initiatives. ## Strategic Focus - **Primary**: Advance VAX-31 and VAX-24 through late-stage clinical trials to secure regulatory approval and establish a new standard of care for pneumococcal disease. - **Pipeline expansion**: Advance VAX-A1 (Group A Strep) and VAX-GI (Shigella) candidates through early clinical development. - **Manufacturing**: Scale up internal manufacturing capabilities to support commercial launch and global supply. - **Commercial readiness**: Building a commercial organization (e.g., hiring a VP of U.S. Market Access & Pricing, Senior Director of Product Launch) to prepare for potential VAX-31 launch. ## Why Work Here - **Culture**: Described as a "kindness-first" mindset with a focus on audacious goals, collaboration, and mutual support. Recognized as a *Great Place to Work* and *Best Workplace in BioPharma* (Fortune). - **Work Model**: Hybrid, Remote, and Onsite options available depending on role. San Carlos HQ offers a hybrid schedule. - **Total Rewards**: 100% paid health, dental, and vision insurance; 401k matching; flexible PTO and holidays; paid parental and sick leave; equity awards (stock options & RSUs); Employee Stock Purchase Plan; lifestyle spending account; mental health and wellness resources. - **Growth & Development**: Strong emphasis on learning culture, professional advancement through coaching, and career development programs. - **Mission-driven**: Employees are directly contributing to creating vaccines that protect every child born and every adult at risk from bacterial infections globally. ## Sources 1. [vaxcyte.com](https://vaxcyte.com/) 2. [vaxcyte.com/careers](https://vaxcyte.com/careers/) 3. [vaxcyte.com/job-listings](https://vaxcyte.com/job-listings/) 4. [vaxcyte.com/culture](https://vaxcyte.com/culture/) 5. [vaxcyte.com/pipeline](https://vaxcyte.com/pipeline/) ## Other roles at Vaxcyte - [Associate Director, Business Process Management & Operational Excellence](https://feeny.ai/job/associate-director-business-process-management-operational-excellence-vaxcyte-5p0t7q2tj3a5) — San Carlos, CA - [Manager, Inventory and Operations Accounting](https://feeny.ai/job/manager-inventory-and-operations-accounting-vaxcyte-san-carlos-r66rjpkp6y1a) — San Carlos, CA - [Senior Accountant](https://feeny.ai/job/senior-accountant-vaxcyte-san-carlos-j4sqgfxb13nj) — San Carlos, CA - [Scientist II (Contract), Analytical Development](https://feeny.ai/job/scientist-ii-contract-analytical-development-vaxcyte-san-carlos-zpsadm0x2qst) — San Carlos, CA - [Systems Engineer](https://feeny.ai/job/systems-engineer-vaxcyte-san-carlos-zy2wf03ynbzs) — San Carlos, CA - [Senior Associate Scientist, Research](https://feeny.ai/job/senior-associate-scientist-research-vaxcyte-san-carlos-908rwbsfgzv7) — San Carlos, CA - [Associate Scientist II, Research](https://feeny.ai/job/associate-scientist-ii-research-vaxcyte-san-carlos-5ytv9687sh0g) — San Carlos, CA - [IT Operations Engineer](https://feeny.ai/job/it-operations-engineer-vaxcyte-san-carlos-y9kstk4b8rz9) — San Carlos, CA - [Manager, Facilities Engineering](https://feeny.ai/job/manager-facilities-engineering-vaxcyte-san-carlos-9z48ebpsa6x8) — San Carlos, CA - [Associate Scientist I, Research](https://feeny.ai/job/associate-scientist-i-research-vaxcyte-san-carlos-k9qmt16gbeaw) — San Carlos, CA